Proceeds from the Offer will be used for:
• Working capital ‒ General working capital that is sufficient for ImpediMed to achieve breakeven, including advance inventory purchases to address growth, current global chip shortages, COVID-19 related supply chain issues and transition to SOZO II
• Product enhancements ‒ SOZO II development, including weight scales and improved electronics for Renal Failure and Heart Failure
• Data and software enhancements ‒ Corporate account development including electronic health record integration and heart failure programs
• Development and commercialisation of renal failure application ‒ End stage renal disease clinical trial and US FDA clearance
I'm happy with this ... glad there were no options!
Ann: Capital Raising Presentation, page-2
Add IPD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
-0.001(1.41%) |
Mkt cap ! $141.6M | |||
| Open | High | Low | Value | Volume |
| 7.2¢ | 7.2¢ | 6.9¢ | $116.5K | 1.668M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9541 | 6.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.0¢ | 439625 | 3 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
6.9¢ |
Change
-0.001 ( 4.17 %) |
||||
| Open | High | Low | Volume | ||
| 7.0¢ | 7.0¢ | 6.9¢ | 79912 | ||
| Last updated 15.57pm 07/06/2024 ? | |||||
| IPD (ASX) Chart |